Tag: Stemline Therapeutics

Home / Stemline Therapeutics

Categories

Elacestrant is approved by FDA for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer

In February 2023, the Food and Drug Administration (FDA) approved elacestrant (Orserdu, Stemline Therapeutics, Inc.) for women or men over 50 who have advanced or metastatic breast cancer and are ER-...
stemline-therapeutics

We Are Online! Chat With Us!
Scan the code